BMC Nephrology · 5 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This prospective pre-post study evaluated medication therapy management (MTM) in 104 hemodialysis patients. The central result was a significant improvement in medication-burden quality of life (MBQoL) and a reduction in drug-related problems and adverse events after three months of MTM services.
This prospective pre-post interventional study assessed the effect of three months of medication therapy management (MTM) services on 104 hemodialysis patients in Egypt. MBQoL was measured using the validated PROMPT questionnaire at baseline and post-intervention. The central result was a significant improvement in MBQoL with a large effect size (Cohen’s d=0.88, p < 0.01). The number of drug-related problems (DRPs) per patient decreased significantly from 11.97 to 7.63 (p < 0.001), and the mean number of adverse events per patient also decreased from 9.69 to 6.56 (p < 0.001). The largest effect was in the domain of medicine information and relation with healthcare providers. University education and post-MTM DRPs were significant predictors of improved MBQoL. The findings suggest that MTM can improve care for hemodialysis patients by reducing medication-related problems and improving patient-reported outcomes.
